Overview
The primary purpose of this study is to investigate the safety of Tasfygo.
Eligibility
Inclusion Criteria:
- Participants with unresectable biliary tract cancer with FGFR2 fusion gene positivity who are naïve to Tasfygo tablet and progressed after chemotherapy.
Exclusion Criteria:
Not applicable.